rs10938397 — GNPDA2

GIANT consortium GWAS obesity locus near GNPDA2

See your personal result for GNPDA2

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

GNPDA2 — The Hexosamine Pathway's Weight Regulator

rs10938397 sits in a regulatory region near GNPDA2 (glucosamine-6-phosphate deaminase 2) on chromosome 4p12 and was identified in the landmark GIANT consortium GWAS11 GIANT consortium GWAS
Willer et al. Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nature Genetics, 2009
as one of six new obesity-associated loci, with a per-allele BMI increase of 0.19 kg/m² and a combined p-value of 3.4×10⁻¹⁶ across 81,758 individuals. The G allele is the risk allele.

The Mechanism

GNPDA2 encodes an allosteric enzyme that catalyzes the reversible conversion of D-glucosamine-6-phosphate to D-fructose-6-phosphate and ammonium. This reaction sits at a critical junction: it opposes the action of GFAT (glutamine-fructose-6-phosphate amidotransferase22 glutamine-fructose-6-phosphate amidotransferase
The rate-limiting enzyme feeding into the hexosamine biosynthesis pathway, which produces UDP-GlcNAc for protein O-GlcNAcylation and cellular signaling
), functioning as a brake on hexosamine flux. The hexosamine pathway is a nutrient sensor — its output, UDP-GlcNAc, modifies proteins and influences insulin signaling, gene expression, and cellular metabolism in proportion to glucose availability.

GNPDA2 is highly expressed in the hypothalamus33 highly expressed in the hypothalamus
Specifically in the arcuate nucleus (ARC), dorsomedial hypothalamus (DMH), lateral hypothalamic area (LHA), and paraventricular nucleus (PVN)
and in adipose tissue, with lower expression in muscle and liver. A 2021 functional study44 2021 functional study
Central administration of a GNPDA2 antagonist into the third ventricle of rats; Frontiers in Nutrition, 2021
showed that central GNPDA2 inhibition does not alter food intake or body weight — ruling out appetite as the primary mechanism — but causes glucose intolerance during an intraperitoneal glucose challenge without changing insulin levels. This positions GNPDA2 as a central regulator of glucose handling, with effects mediated through insulin sensitivity rather than insulin secretion or appetite drive.

In adipose tissue, the picture is complementary: a 2019 study55 2019 study
Wu et al. GNPDA2 Gene Affects Adipogenesis and Alters the Transcriptome Profile of Human Adipose-Derived Mesenchymal Stem Cells. International Journal of Endocrinology, 2019
demonstrated that overexpression of GNPDA2 in human adipose-derived mesenchymal stem cells enhances lipid droplet accumulation and adipocyte differentiation, while knockdown suppresses adipogenesis. The transcriptome changes affected genes involved in fatty acid metabolism, lipid modification, and glucose homeostasis.

The Evidence

The association is among the most robustly replicated in obesity genetics. The original GIANT discovery in 32,000 European subjects with replication in 59,000 more66 32,000 European subjects with replication in 59,000 more
Willer et al. Nature Genetics, 2009
was confirmed in a 249,796-individual meta-analysis (Speliotes et al. Nature Genetics, 201077 Speliotes et al. Nature Genetics, 2010) and the largest BMI GWAS to date, 339,224 individuals88 339,224 individuals
Locke et al. Nature, 2015
.

In a Danish cohort of 18,014 adults, the G allele was associated with OR 1.15 for obesity (p = 1.1×10⁻⁴)99 OR 1.15 for obesity (p = 1.1×10⁻⁴)
Sandholt et al. Studies of Metabolic Phenotypic Correlates of 15 Obesity Associated Gene Variants. PLOS ONE, 2011
, BMI increase of 0.28 kg/m² per allele, and a 0.61 cm increase in waist circumference. Nominal associations with fasting insulin and HOMA-IR1010 HOMA-IR
Homeostatic Model Assessment of Insulin Resistance — a measure of insulin sensitivity derived from fasting glucose and insulin
were also observed but did not survive correction for multiple testing.

In Mexican children, the association was stronger: OR 1.30 for obesity (p = 1.34×10⁻³)1111 OR 1.30 for obesity (p = 1.34×10⁻³)
Mejia-Benitez et al. BMC Medical Genetics, 2013
. A Chinese study found the G allele associated with increased BMI, fat mass percentage, and waist-to-height ratio in children, with effects varying by sex and pubertal stage.

The G allele frequency is approximately 0.43 in Europeans (risk allele frequency 41% in the Danish cohort) — making this a very common variant. The GG genotype, carrying the highest risk, occurs in ~18% of Europeans.

Interactions

rs10938397 contributes to a polygenic obesity risk profile alongside FTO (rs9939609), MC4R (rs17782313), TMEM18 (rs6548238), and NEGR1 (rs2815752). GWAS evidence indicates these effects are additive: carrying risk alleles at multiple loci compounds the BMI increase, and a person with risk alleles at GNPDA2 plus FTO or MC4R faces a higher cumulative genetic burden than at either locus alone. No synergistic (multiplicative) interaction has been documented among these loci — their combined effect is the sum of their individual contributions.

Nutrient Interactions

glucose altered_metabolism
fructose-6-phosphate altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant.

AA Lower Genetic Obesity Risk Normal

No risk alleles at GNPDA2 — lower genetic tendency for hexosamine-mediated weight gain

You carry two copies of the A allele, the protective form at rs10938397. About 32% of Europeans share this genotype.

The GNPDA2 obesity locus contributes ~0.19 kg/m² BMI per risk allele — your AA genotype avoids both copies of this increment, placing you at the favorable end of the GNPDA2 spectrum.

AG Moderate GNPDA2 Risk Intermediate

One risk allele — modestly elevated BMI tendency from hexosamine pathway variation

Heterozygotes carry an intermediate genetic load at this locus. In the Danish Inter99 cohort (n=6,039), each G allele was associated with 0.28 kg/m² higher BMI, 0.61 cm greater waist circumference, and nominal increases in fasting insulin and HOMA-IR (insulin resistance marker). The effect on waist circumference alongside BMI suggests that GNPDA2 contributes to central adiposity specifically, not simply overall weight.

GG Higher GNPDA2 Risk High Risk

Two risk alleles — highest genetic loading for GNPDA2-mediated metabolic adiposity

GG homozygotes carry the full two-allele burden at this GWAS locus. In adults, the Danish Inter99 cohort found the G allele associated with OR 1.15 for obesity per allele (compounding to approximately OR 1.32 for GG vs AA). In Mexican children, the OR was 1.30 per allele. Waist circumference data suggests central adiposity is particularly affected.